Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : BLUE    crawled time : 14:30    save search
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2021-11-22 (Crawled : 14:30) - biospace.com/
BLUE | $0.9536 -6.51% -6.61% 4.2K twitter stocktwits trandingview |
Health Technology
 | | O: 5.7% H: 0.44% C: -6.81%
fda blood transfusion application gene therapy therapy license cel
Gainers vs Losers
73% 27%

Top 10 Gainers
AGBA | $2.5 100.0% 58.33% 200M twitter stocktwits trandingview |
Finance
EDBL | News | $6.26 66.49% 48.56% 270K twitter stocktwits trandingview |

SILO | $1.99 0.71% 20.64% 1.8M twitter stocktwits trandingview |
Finance and Insurance
CANG | $1.34 -4.29% 14.93% 120K twitter stocktwits trandingview |
Technology Services
AZTR 4 | $0.195 13.85% 42K twitter stocktwits trandingview |
n/a
TOVX | News | $0.411 -1.01% 12.9% 230K twitter stocktwits trandingview |
Manufacturing
IBRX | $4.94 -6.26% 10.83% 4.5M twitter stocktwits trandingview |
Manufacturing
CISS | $1.3 11.11% 10.0% 42K twitter stocktwits trandingview |
n/a
SQNS | $0.504 -9.19% 9.25% 110K twitter stocktwits trandingview |
Electronic Technology
CR | $130.73 0.97% 8.82% 230K twitter stocktwits trandingview |
Producer Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.